| Detected | Trial | Change |
|---|---|---|
| 2026-05-29 | NCT05396833 Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune… |
date change Primary completion pushed: 2026-04-10 -> 2027-01-14 |
| 2026-05-29 | NCT05396833 Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune… |
date change Completion pushed: 2026-04-10 -> 2027-01-14 |
| 2026-05-28 | NCT06225596 Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer… |
Phase changed: ['PHASE2', 'PHASE3'] -> ['PHASE2'] |
| 2026-05-28 | NCT06225596 Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer… |
Primary endpoint(s) modified |
| 2026-05-28 | NCT06225596 Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer… |
Enrollment reduced: 956 -> 375 participants |
| 2026-05-28 | NCT06225596 Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer… |
Trial arms changed: 6 -> 5 |
| 2026-05-28 | NCT06225596 Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer… |
date change Primary completion moved earlier: 2030-12 -> 2028-03 |
| 2026-05-28 | NCT06225596 Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer… |
date change Completion moved earlier: 2030-12 -> 2028-03 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT04637594 | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy | Locally Advanced Bladder Urothelial Carcinoma | Active, Not Recruiting |
| NCT03815643 | Avelumab Program Rollover Study | Solid Tumors | Active, Not Recruiting |
| NCT05059522 | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab… | Advanced Malignancies | Active, Not Recruiting |
| NCT03271372 | Adjuvant Avelumab in Merkel Cell Cancer | Stage III Merkel Cell Carcinoma AJCC v8 | Active, Not Recruiting |
| NCT05092958 | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy… | Advanced Bladder Urothelial Carcinoma | Active, Not Recruiting |
| Phase 2 | |||
| NCT06518564 | Avelumab and M1774 in ARID1A-mutated Endometrial Cancer | Endometrial Cancer | Recruiting |
| NCT03547973 | Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be… | Metastatic Urothelial Cancer | Recruiting |
| NCT04841148 | Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast… | Breast Cancer | Recruiting |
| NCT07110038 | DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab… | Penile Squamous Cell Carcinoma (PSCC) | Recruiting |
| NCT05327686 | Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the… | Metastatic Renal Cell Carcinoma | Recruiting |
| NCT06892860 | Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in… | Urinary Bladder Neoplasms | Recruiting |
| NCT06228066 | Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) | Small Cell Carcinoma of the Bladder | Recruiting |
| NCT03744793 | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial… | Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant | Active, Not Recruiting |
| NCT04848519 | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With… | Locally Advanced Bladder Urothelial Carcinoma | Active, Not Recruiting |
| NCT07460245 | Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic… | Urothelial Carcinoma | Not Yet Recruiting |
| NCT03573648 | Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast… | Breast Cancer | Active, Not Recruiting |
| NCT04792073 | Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma | Merkel Cell Carcinoma | Active, Not Recruiting |
| NCT04291885 | Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma | Merkel Cell Carcinoma | Active, Not Recruiting |
| NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating… | Stage III Breast Cancer | Active, Not Recruiting |
| NCT05327530 | A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in… | Locally Advanced or Metastatic Urothelial Carcinoma | Active, Not Recruiting |
| NCT05947500 | Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to… | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Active, Not Recruiting |
| NCT06225596 | Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer… | Metastatic Urothelial Cancer | Active, Not Recruiting |
| NCT03076554 | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C)… | Thymoma | Active, Not Recruiting |
| NCT03944941 | Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell… | Skin Squamous Cell Carcinoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT02813135 | European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in… | Pediatric Cancer | Recruiting |